Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
WVE 
Wave Life Sciences Ltd (WVE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: WVE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $20.38
1 Year Target Price $20.38
| 9 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.06% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.04B USD | Price to earnings Ratio - | 1Y Target Price 20.38 |
Price to earnings Ratio - | 1Y Target Price 20.38 | ||
Volume (30-day avg) 13 | Beta -1.05 | 52 Weeks Range 5.04 - 16.73 | Updated Date 06/30/2025 |
52 Weeks Range 5.04 - 16.73 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -107.04% | Operating Margin (TTM) -542.82% |
Management Effectiveness
Return on Assets (TTM) -30.02% | Return on Equity (TTM) -105.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 818126975 | Price to Sales(TTM) 9.89 |
Enterprise Value 818126975 | Price to Sales(TTM) 9.89 | ||
Enterprise Value to Revenue 7.8 | Enterprise Value to EBITDA -10.12 | Shares Outstanding 155563008 | Shares Floating 67644850 |
Shares Outstanding 155563008 | Shares Floating 67644850 | ||
Percent Insiders 16.25 | Percent Institutions 84.41 |
Analyst Ratings
Rating 4 | Target Price 20.38 | Buy 3 | Strong Buy 9 |
Buy 3 | Strong Buy 9 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Wave Life Sciences Ltd
Company Overview
History and Background
Wave Life Sciences Ltd. was founded in 2012. It is a biotechnology company focused on developing stereopure oligonucleotide therapeutics for genetically defined diseases.
Core Business Areas
- Neurological Disorders: Development of therapies for neurological disorders like Huntington's disease and Duchenne muscular dystrophy (DMD).
- Genetic Medicine: Development of stereopure oligonucleotides aimed at treating genetically defined diseases.
Leadership and Structure
Paul B. Bolno is the CEO. The company has a typical organizational structure for a biotechnology company, including research, development, clinical, and commercial teams. Board of directors oversees the company's strategic direction.
Top Products and Market Share
Key Offerings
- WVE-N531: An exon-skipping therapy for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. Phase 2/3 clinical trials are ongoing. Competitors include Sarepta Therapeutics and NS Pharma who also target DMD.
- WVE-003: A stereopure siRNA targeting HTT for the treatment of Huntington's disease. Program discontinued in 2021 after Phase 1b/2a study. Competitors include Roche (Tominersen), which was also discontinued.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk and high reward. Companies focus on developing novel therapeutics for unmet medical needs. It is research and development intensive with a lengthy regulatory approval process.
Positioning
Wave Life Sciences Ltd is positioned as a company specializing in stereopure oligonucleotide therapeutics. Their competitive advantage lies in their expertise in designing and developing these types of therapies.
Total Addressable Market (TAM)
The TAM for neurological disorders and genetic diseases is substantial, reaching billions of dollars. Wave is focusing on niche, genetically defined segments of these markets.
Upturn SWOT Analysis
Strengths
- Stereopure oligonucleotide technology
- Focus on genetically defined diseases
- Experienced management team
Weaknesses
- High cash burn rate
- Dependence on clinical trial success
- Limited commercialized products
- Prior clinical trial failures
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in oligonucleotide delivery technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent disputes
Competitors and Market Share
Key Competitors
- SRPT
- BMY
- NS Pharma
Competitive Landscape
Wave Life Sciences has a competitive advantage with its stereopure oligonucleotide technology. However, it faces significant competition from larger, more established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by progress in clinical trials and securing funding through partnerships and equity offerings.
Future Projections: Future growth is contingent on the successful development and commercialization of its pipeline products.
Recent Initiatives: Focusing on WVE-N531 for DMD, pursuing strategic partnerships.
Summary
Wave Life Sciences is a biotechnology company focused on developing oligonucleotide therapeutics with notable clinical trial failures. The company's future is strongly tied to the success of WVE-N531. Its stereopure technology offers a potential advantage, but it has high cash burn and needs a robust partnership strategy to compete effectively. Overall, the company is high risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial professional. Market share data are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Wave Life Sciences Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-11-11 | President, CEO & Director Dr. Paul B. Bolno M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 287 | Website https://wavelifesciences.com |
Full time employees 287 | Website https://wavelifesciences.com | ||
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.